WO2001051066A3 - Reduction in bacterial colonization by administering bacteriophage compositions - Google Patents

Reduction in bacterial colonization by administering bacteriophage compositions Download PDF

Info

Publication number
WO2001051066A3
WO2001051066A3 PCT/US2001/000809 US0100809W WO0151066A3 WO 2001051066 A3 WO2001051066 A3 WO 2001051066A3 US 0100809 W US0100809 W US 0100809W WO 0151066 A3 WO0151066 A3 WO 0151066A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
patient
susceptible
bacteriophage
reduction
Prior art date
Application number
PCT/US2001/000809
Other languages
French (fr)
Other versions
WO2001051066A2 (en
Inventor
Glenn J Morris
Zemphira Alavidze
Alexander Sulakvelidze
Gary R Pasternack
Torrey C Brown
Original Assignee
Intralytix Inc
Glenn J Morris
Zemphira Alavidze
Alexander Sulakvelidze
Gary R Pasternack
Torrey C Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intralytix Inc, Glenn J Morris, Zemphira Alavidze, Alexander Sulakvelidze, Gary R Pasternack, Torrey C Brown filed Critical Intralytix Inc
Priority to EP01922226A priority Critical patent/EP1250143A2/en
Priority to AU2001249050A priority patent/AU2001249050A1/en
Priority to CA002430498A priority patent/CA2430498A1/en
Publication of WO2001051066A2 publication Critical patent/WO2001051066A2/en
Publication of WO2001051066A3 publication Critical patent/WO2001051066A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/12—Polyester-amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
    • A23B4/00—General methods for preserving meat, sausages, fish or fish products
    • A23B4/14—Preserving with chemicals not covered by groups A23B4/02 or A23B4/12
    • A23B4/18—Preserving with chemicals not covered by groups A23B4/02 or A23B4/12 in the form of liquids or solids
    • A23B4/20—Organic compounds; Microorganisms; Enzymes
    • A23B4/22—Microorganisms; Enzymes; Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
    • A23B7/00—Preservation or chemical ripening of fruit or vegetables
    • A23B7/14—Preserving or ripening with chemicals not covered by groups A23B7/08 or A23B7/10
    • A23B7/153—Preserving or ripening with chemicals not covered by groups A23B7/08 or A23B7/10 in the form of liquids or solids
    • A23B7/154—Organic compounds; Microorganisms; Enzymes
    • A23B7/155—Microorganisms; Enzymes; Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/04—Production of frozen sweets, e.g. ice-cream
    • A23G9/22—Details, component parts or accessories of apparatus insofar as not peculiar to a single one of the preceding groups
    • A23G9/30—Cleaning; Keeping clean; Sterilisation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/34635—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3571—Microorganisms; Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/22—Phase substances, e.g. smokes, aerosols or sprayed or atomised substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacterial subject to infection by said bacteriophage.
PCT/US2001/000809 2000-01-11 2001-01-11 Reduction in bacterial colonization by administering bacteriophage compositions WO2001051066A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01922226A EP1250143A2 (en) 2000-01-11 2001-01-11 Reduction in bacterial colonization by administering bacteriophage compositions
AU2001249050A AU2001249050A1 (en) 2000-01-11 2001-01-11 Reduction in bacterial colonization by administering bacteriophage compositions
CA002430498A CA2430498A1 (en) 2000-01-11 2001-01-11 Reduction in bacterial colonization by administering bacteriophage compositions

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US17541500P 2000-01-11 2000-01-11
US17541600P 2000-01-11 2000-01-11
US17537700P 2000-01-11 2000-01-11
US60/175,416 2000-01-11
US60/175,377 2000-01-11
US60/175,415 2000-01-11
US20524000P 2000-05-19 2000-05-19
US60/205,240 2000-05-19

Publications (2)

Publication Number Publication Date
WO2001051066A2 WO2001051066A2 (en) 2001-07-19
WO2001051066A3 true WO2001051066A3 (en) 2002-01-10

Family

ID=27497136

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2001/000810 WO2001050866A2 (en) 2000-01-11 2001-01-11 Method and device for sanitation using bacteriophages
PCT/US2001/000809 WO2001051066A2 (en) 2000-01-11 2001-01-11 Reduction in bacterial colonization by administering bacteriophage compositions
PCT/US2001/000807 WO2001051027A2 (en) 2000-01-11 2001-01-11 Polymer blends as biodegradable matrices for preparing biocomposites
PCT/US2001/000811 WO2001050872A2 (en) 2000-01-11 2001-01-11 Method for produce sanitation using bacteriophages

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000810 WO2001050866A2 (en) 2000-01-11 2001-01-11 Method and device for sanitation using bacteriophages

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2001/000807 WO2001051027A2 (en) 2000-01-11 2001-01-11 Polymer blends as biodegradable matrices for preparing biocomposites
PCT/US2001/000811 WO2001050872A2 (en) 2000-01-11 2001-01-11 Method for produce sanitation using bacteriophages

Country Status (10)

Country Link
US (6) US6699701B1 (en)
EP (5) EP1250053A2 (en)
JP (1) JP2003519650A (en)
KR (1) KR20030009338A (en)
CN (1) CN1230206C (en)
AT (2) ATE280499T1 (en)
AU (4) AU2001229342A1 (en)
CA (4) CA2430500A1 (en)
DE (2) DE60116052T2 (en)
WO (4) WO2001050866A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835384B (en) * 2007-10-04 2014-07-16 诺沃莱蒂克斯有限公司 Anti-bacteria compositions

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039111A1 (en) * 1996-04-15 1997-10-23 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2427928A1 (en) * 2000-11-02 2002-12-27 New Horizons Diagnostics Corporation The use of bacterial phage associated lytic enzymes to prevent food poisoning
GB0028130D0 (en) 2000-11-17 2001-01-03 Phico Therapeutics Ltd Polypeptide and uses thereof
US7168629B2 (en) * 2001-02-28 2007-01-30 Peter Timmes Scuba gear sanitizing method
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US7232564B2 (en) * 2001-07-18 2007-06-19 Instytut Immunologii I Terapii Doswiadczal-Nej Pan Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
BR0214928A (en) * 2001-12-13 2004-11-30 Nestle Sa Isolated phages and their use in food and feed
GB0207021D0 (en) * 2002-03-25 2002-05-08 Univ Warwick Anti-bacterial agents
ATE370228T1 (en) * 2002-03-25 2007-09-15 Univ Warwick BACTERIOPHAGES SUITABLE FOR THE THERAPY AND PROPHYLAXIS OF BACTERIAL INFECTIONS
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7776926B1 (en) 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7758880B2 (en) 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
CA2511492A1 (en) * 2002-12-23 2004-07-15 The Rockefeller University Use of synergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections
US7951579B2 (en) 2003-04-07 2011-05-31 Board of Trutees of the University of Arkansas Method for bacteriophage delivery and amplification
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
ES2556243T3 (en) 2003-07-23 2016-01-14 Biocontrol Limited Therapeutic agents containing bacteriophages
US7674467B2 (en) * 2003-09-03 2010-03-09 Intralytix, Inc. Salmonella bacteriophage and uses thereof
GB0320838D0 (en) 2003-09-05 2003-10-08 Univ Nottingham Disinfection of foodstuffs
DE10342071B4 (en) * 2003-09-10 2006-01-19 Fleischmann, Wilhelm, Dr.med. Device and method for applying substances to a wound surface
US7311207B2 (en) * 2003-09-19 2007-12-25 Vesta Medical, Llc System for sorting discarded and spent pharmaceutical items
US7303081B2 (en) * 2003-09-19 2007-12-04 Vesta Medical, Llc Handheld medical waste sorting method
US7275645B2 (en) * 2003-09-19 2007-10-02 Vesta Medical, Llc Handheld medical waste sorting device
US7562025B2 (en) 2003-09-19 2009-07-14 Vesta Medical, Llc Waste sorting system with query function, and method thereof
US8195328B2 (en) 2003-09-19 2012-06-05 Vesta Medical, Llc Combination disposal and dispensing apparatus and method
WO2005029286A2 (en) * 2003-09-19 2005-03-31 Vesta Medical, Llc System and method for sorting medical waste for disposal
US7318529B2 (en) * 2003-09-19 2008-01-15 Vest Medical, Llc Method for sorting discarded and spent pharmaceutical items
US7660724B2 (en) 2003-09-19 2010-02-09 Vesta Medical, Llc Waste sorting system utilizing removable liners
WO2005046579A2 (en) * 2003-10-06 2005-05-26 Gangagen, Inc. Defined dose therapeutic phage
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005094909A1 (en) * 2004-03-23 2005-10-13 Steris Inc. Integrated control and distribution system for the decontamination of large volume, convoluted configuration spaces
US20050255043A1 (en) * 2004-04-09 2005-11-17 Hnatowich Donald J Bacteriophage imaging of inflammation
US20050265960A1 (en) * 2004-05-26 2005-12-01 Pacetti Stephen D Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US7563780B1 (en) 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
US7494665B1 (en) 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
US7795000B2 (en) 2004-09-24 2010-09-14 Ecolab Inc. Foaming composition of competitive exclusion microbes and methods of using same
US7166680B2 (en) * 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US20060075975A1 (en) * 2004-10-08 2006-04-13 Schneider David J Animal litter
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US7390497B2 (en) * 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
WO2006050193A2 (en) * 2004-11-01 2006-05-11 Strategic Diagnostics, Inc. Bacteriophages as selective agents
BRPI0515769A (en) * 2004-11-02 2008-07-29 Gangagen Life Sciences Inc bacteriophage compositions
MX2007005277A (en) * 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Stabilized bacteriophage formulations.
WO2006063176A2 (en) * 2004-12-06 2006-06-15 The Government Of The Usa As Representedtd By The Secretary Of The Dept Of Health And Human Services Inhibition of biofilm formation using bacteriophage
US7604818B2 (en) 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US20060153811A1 (en) * 2005-01-10 2006-07-13 Jackson Lee E Use of viruses and virus-resistant microorganisms for controlling microorganism populations
CA2495138C (en) * 2005-01-20 2012-10-23 Alison Jane Basile Multiplexed analysis for determining a serodiagnosis of viral infection
EP1848410A4 (en) * 2005-02-17 2011-11-09 Medivas Llc Polymer particle delivery compositions and methods of use
CN100409012C (en) * 2005-03-18 2008-08-06 南开大学 Fast detection of degradation property for biological degradation materials by utilizing bacteriological hybrid bacterium group
JP2008542393A (en) * 2005-06-03 2008-11-27 メディバス エルエルシー Therapeutic polymers and methods of use
AU2006268420B2 (en) 2005-07-12 2012-06-28 Micreos B.V. Bacteriophage and their uses
JP5192384B2 (en) 2005-09-22 2013-05-08 メディバス エルエルシー Bis- (α-amino) -diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007044428A2 (en) * 2005-10-05 2007-04-19 Internalle, Inc. Method for liberating bacteriophages and uses thereof
JP5445130B2 (en) * 2006-05-02 2014-03-19 メディバス エルエルシー Delivery of ophthalmic drugs to the exterior or interior of the eye
JP5196498B2 (en) * 2006-05-09 2013-05-15 メディバス エルエルシー Biodegradable water-soluble polymer
US8445639B2 (en) 2006-05-15 2013-05-21 Avidbiotics Corporation Recombinant bacteriophage and methods for their use
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US7390404B2 (en) * 2006-09-19 2008-06-24 Abcusa Environmental Holdings, Inc. Apparatus and method for remediation of a drain system
US7300583B1 (en) 2006-09-19 2007-11-27 Abcusa Environmental Holdings, Inc. Apparatus and method for remediation of a waste stream
FR2910492B1 (en) 2006-12-20 2013-02-15 Bio Modeling Systems Ou Bmsystems PROCESS FOR THE PREPARATION OF MODIFIED BACTERIOPHAGES BY INSERTION OF RANDOM SEQUENCES IN THE TARGETING PROTEINS OF SAID BACTERIOPHAGES
MX2009009246A (en) * 2007-02-28 2010-02-12 Omnilytics Inc External animal layer sanitation using bacteriophage.
GB0704553D0 (en) 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US7635584B2 (en) * 2007-05-31 2009-12-22 Intralytix, Inc. E. coli O157:H7 bacteriophage and uses thereof
US7622293B2 (en) * 2007-06-18 2009-11-24 Intralytix, Inc. Pseudomonas aeruginosa: bacteriophage and uses thereof
GB2450535A (en) * 2007-06-29 2008-12-31 Laurence Campion Packaging (by encasing with a fluid composition) method and apparatus
US20090081173A1 (en) * 2007-08-10 2009-03-26 The Board Of Regents Of The University Of Texas System Methods and compositions involving bacteriophage isolates
US20090104157A1 (en) * 2007-10-05 2009-04-23 E. I. Du Pont De Nemours And Company Utilization of bacteriophage to control bacterial contamination in fermentation processes
US7625741B2 (en) * 2007-12-12 2009-12-01 Intralytix, Inc. E. coli O157:H7 bacteriophage and uses thereof
US7625556B2 (en) * 2007-12-12 2009-12-01 Intralytix, Inc. E. coli bacteriophage and uses thereof
WO2009075884A1 (en) * 2007-12-12 2009-06-18 Intralytix, Inc. Novel e. coli bacteriophages and uses thereof
US8956628B2 (en) 2007-12-13 2015-02-17 Zoetis Products Llc Bacteriophage preparations and method of use thereof
US9320795B2 (en) * 2007-12-13 2016-04-26 Zoctis Server LLC Bacteriophage preparations and methods of use thereof
US9056899B2 (en) 2008-01-10 2015-06-16 Trustees Of Boston University Engineered bacteriophages as adjuvants for antimicrobial agents and compositions and methods of use thereof
DE102008005193A1 (en) * 2008-01-18 2009-07-23 Dahlen, Neithard Bacteriophage preparation and use
EP2103308A1 (en) * 2008-03-20 2009-09-23 PhytoLine GmbH Method for producing a mixture of bacteriophages and its use in therapy of antibiotic-resistant staphylococci
US9486007B2 (en) 2008-03-25 2016-11-08 Ecolab Usa Inc. Bacteriophage treatment for reducing and preventing bacterial contamination
US20090272025A1 (en) * 2008-05-01 2009-11-05 Wolosuk Susan Marie Disinfectant household bomb
WO2009155450A2 (en) * 2008-06-20 2009-12-23 Board Of Regents, The University Of Texas System Biodegradable photoluminescent polymers
CN101342383B (en) * 2008-08-25 2011-09-14 四川国纳科技有限公司 Tissue renovation material of polymer form and preparation method thereof
US7745194B2 (en) * 2008-09-16 2010-06-29 Intralytix, Inc. Staphylococcus aureus: bacteriophage and uses thereof
CN101417149B (en) * 2008-10-22 2012-11-21 四川大学 Degradable biological composite material of phosphate containing calcium and preparation method thereof
BRPI1008663B8 (en) 2009-02-06 2021-05-25 Technophage Investig E Desenvolvimento Em Biotecnologia S A bacteriophage with a genome, pharmaceutical composition, use of a therapeutically effective amount of the pharmaceutical composition, method of diagnosing the causative agent of a bacterial infection, and use of the bacteriophage
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
US8241498B2 (en) * 2009-03-28 2012-08-14 Phage Biocontrol Research, Llc Process for remediating biofouling in water systems with virulent bacteriophage
US20100330041A1 (en) * 2009-05-27 2010-12-30 Bayrock Dennis P Viral-based antimicrobial agent use in ethanol production
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US20110027417A1 (en) 2009-07-31 2011-02-03 Patrick Joseph Corrigan Process for Dusting Animal Food
TWI380777B (en) * 2009-08-12 2013-01-01 Tzu Chi Buddhist General Hospital Bactericide composition comprising a phage
US20120276612A1 (en) 2009-08-12 2012-11-01 Tzu Chi Buddhist General Hospital Phage of acinetobacter baumannii
US8168419B2 (en) 2010-01-14 2012-05-01 Phage Biocontrol Research, Llc Prevention and remediation of petroleum reservoir souring and corrosion by treatment with virulent bacteriophage
TW201130980A (en) * 2010-03-02 2011-09-16 Univ Ishou A new lytic phage specific to Klebsiella pneumoniae
US8241499B2 (en) 2010-03-08 2012-08-14 Phage Biocontrol Research, Llc Control of filamentous bacteria induced foaming in wastewater systems
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
KR101206408B1 (en) 2010-08-04 2012-11-29 서울대학교산학협력단 Bacteriophage killing Salmonella and Escherichia coli O157 and bacteriocidal composition comprising the same
US8252576B2 (en) 2010-08-11 2012-08-28 Phage Biocontrol Research, Llc Use of prokaryote viruses to remediate bio-fouling
US8252519B2 (en) 2010-08-12 2012-08-28 Phage Biocontrol Research, Llc Process for continuous production of bacteriophage
US9650272B2 (en) 2010-12-31 2017-05-16 Dow Global Technologies Llc Prevention and remediation of petroleum reservoir souring and corrosion by treatment with virulent bacteriophage
WO2012159774A1 (en) * 2011-05-26 2012-11-29 Dsm Ip Assets B.V. Novel listeria bacteriophage p825n and uses thereof
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CA2839526A1 (en) 2011-06-23 2012-12-27 Dsm Ip Assets B.V. Micro- or nanoparticles comprising a biodegradable polyesteramide copolymer for use in the delivery of bioactive agents
CA2925546C (en) 2012-10-29 2022-06-14 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
EP2958575B1 (en) * 2013-02-22 2019-04-03 The Regents of The University of California Composition comprising lactobaccilus johnsonii 456 and its use in treating or preventing diseases
US10413577B2 (en) 2013-02-22 2019-09-17 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
US9464267B2 (en) 2013-03-14 2016-10-11 Dow Global Technologies Llc Staged bacteriophage remediation of target bacteria
CA2907234A1 (en) 2013-03-15 2014-09-25 Altria Client Services Llc Bacteriophage and methods of making and using
DE102013106455A1 (en) * 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Method for decontamination of bacteriological contaminants
CN105338819A (en) 2013-06-27 2016-02-17 星巴克公司，贸易用名星巴克咖啡公司 Biopreservation methods for beverages and other foods
WO2015093957A2 (en) * 2013-12-18 2015-06-25 Bacsassin B.V. Bacteria clearance with fogged bacteriophage.
EP3096620A1 (en) * 2014-01-24 2016-11-30 The Procter & Gamble Company Fibrous structures comprising a surface care composition and a bacteriophage
US9937087B2 (en) 2014-01-24 2018-04-10 The Procter & Gamble Company Disposable absorbent articles comprising skin health composition(s) and related methods
EP3096841B1 (en) 2014-01-24 2018-04-11 The Procter and Gamble Company Skin care wipes comprising added natural antibacterial agents
US11252966B2 (en) 2014-01-24 2022-02-22 The Procter & Gamble Company Fibrous structures comprising a surface care composition and methods for making and using same
US10111458B1 (en) 2014-05-16 2018-10-30 R.J. Reynolds Tobacco Company Process for inhibiting formation of nitrosamines
CA2901690A1 (en) 2014-08-27 2016-02-27 The Governors Of The University Of Alberta Bacteriophage-based biosensor for microbial detection
WO2016081645A1 (en) * 2014-11-19 2016-05-26 San Diego State University (Sdsu) Foundation Antibacterial and protective formulations and methods for making and using them
CA2969171C (en) 2014-12-18 2023-12-12 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
EP3253215B1 (en) * 2015-01-23 2023-06-14 Intralytix, Inc. Novel shigella bacteriophages and uses thereof
US9781929B2 (en) 2015-01-29 2017-10-10 Altria Client Services Llc Bacteriophage and methods of using
US10357056B2 (en) 2015-01-29 2019-07-23 Altria Client Services Llc Endolysin from bacteriophage against Geobacillus and methods of using
US11058131B2 (en) 2015-04-16 2021-07-13 Kennesaw State University Research And Service Foundation, Inc. Escherichia coli O157:H7 bacteriophage Φ241
CN107529789A (en) 2015-04-28 2018-01-02 马斯公司 The method for preparing sterilizing wet pet foodstuffs
EP4169383A1 (en) 2015-05-06 2023-04-26 SNIPR Technologies Limited Altering microbial populations & modifying microbiota
WO2017079715A1 (en) * 2015-11-06 2017-05-11 Micro-Nature, Inc. Systems, methods,and compositions for using bacterialfood-safety preparations to promote safetyand preservation of foods, beverages, and non-edible surfaces
EP3436611A4 (en) 2016-04-01 2019-11-06 Tufts University Methods and compositions for preventing infection by a vibrio species
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US10849944B2 (en) * 2016-06-23 2020-12-01 Phagelux (Canada) Inc. Microencapsulation of bacteriophages and related products
NL1042018B1 (en) * 2016-08-26 2018-03-06 Bacsassin B V Patent Bacteria Detection and Elimination according to SID
WO2018198051A1 (en) * 2017-04-26 2018-11-01 Phagelux (Canada) Inc. Plasma immobilization of bacteriophages and applications thereof
EP3461345A1 (en) * 2017-09-28 2019-04-03 Fixed Phage Limited Anti-bacterial packaging
WO2019092847A1 (en) * 2017-11-10 2019-05-16 横河電機株式会社 Microbial contamination countermeasure selection device, system, method, and program
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3886593A4 (en) * 2019-10-23 2022-03-23 Ankara Üniversitesi Rektörlügü Bacteriophage cocktail for listeria monocytogenes and escherichia coli
DE102019134489A1 (en) * 2019-12-16 2021-06-17 Fachhochschule Südwestfalen Phage cultivation device, method for preparing phage and filter device therefor
CN113755450B (en) * 2021-09-03 2023-06-27 广西大学 Escherichia coli phage GN4-1 and application thereof
CN114276571B (en) * 2022-01-13 2023-06-27 四川省食品发酵工业研究设计院有限公司 Antibacterial antioxidant degradable preservative film and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414304A2 (en) * 1989-08-21 1991-02-27 Unilever N.V. Aqueous antibacterial compositions comprising surfactant and bacteriophage
WO1995027043A1 (en) * 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
WO1997039111A1 (en) * 1996-04-15 1997-10-23 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
DE19828596A1 (en) * 1997-06-26 1999-02-11 A Daniela Dr Nodar Use of polyvalent bacteriophages
WO2000069269A1 (en) * 1999-05-13 2000-11-23 Exponential Biotherapies, Inc. Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1590A (en) * 1840-05-08 Shaking the screen ob
US2876108A (en) 1955-11-03 1959-03-03 Swift & Co Processing of food materials
US3121036A (en) * 1958-02-28 1964-02-11 Canada Iron Ore Co Explosive composition comprising ammonium nitrate and a heat-producing metal
US4375734A (en) 1981-08-17 1983-03-08 University Patents, Inc. Protection of plants against frost injury using ice nucleation-inhibiting species-specific bacteriophages
JPS60159596A (en) * 1984-01-30 1985-08-21 Agency Of Ind Science & Technol Prevention of stain by living organism
JPS62123104A (en) * 1985-11-22 1987-06-04 Japan Tobacco Inc Control of soil bright to solanaceous plant
DE3714699A1 (en) * 1986-05-06 1988-01-07 Willi Dipl Ing Benz Spray device connected to a pressurised-water line
JPS62298498A (en) * 1986-06-18 1987-12-25 Agency Of Ind Science & Technol Method for preventing pollution of marine organisms by injection of deposited phage
US4828999A (en) * 1986-07-21 1989-05-09 Jackson Le Roy E Bacteriophage prevention and control of harmful plant bacteria
GB8710795D0 (en) 1987-05-07 1987-06-10 Microbial Dev Ltd Antimicrobial preparations
EP0290295B1 (en) * 1987-05-07 1992-08-05 Microbial Developments Limited Antimicrobial preparations
JPH01163108A (en) * 1987-12-21 1989-06-27 Kansai Electric Power Co Inc:The Method for preventing fouling with marine life
US4891210A (en) 1989-01-03 1990-01-02 Norris Alan H Use of bacteriophages in dental hygiene
US5573801A (en) * 1989-02-21 1996-11-12 Viskase Corporation Surface treatment of foodstuffs with antimicrobial compositions
US5132221A (en) 1989-05-10 1992-07-21 The United States Of America As Represented By The United States Department Of Energy Lysogenic bacteriophage isolated from acidophilium
US5206015A (en) * 1989-06-05 1993-04-27 The United States Of America As Represented By The Secretary Of Agriculture Introduction of bacteria in ovo
GB8913657D0 (en) 1989-06-14 1989-08-02 Microbial Dev Ltd Ruminant feedstuff additives
US4957686A (en) 1990-02-06 1990-09-18 Norris Alan H Use of bacteriophages to inhibit dental caries
DE69004415D1 (en) * 1990-03-05 1993-12-09 Minnesota Mining & Mfg Device for delayed delivery of pharmacologically active compounds into the ear.
JPH0667886B2 (en) * 1990-08-21 1994-08-31 エム・ディ・リサーチ株式会社 Polymer compound
GB2253859A (en) * 1991-02-28 1992-09-23 Microbial Dev Ltd Use of bacteriophages to prevent microbial infestation
GB2255561B (en) * 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
US5869113A (en) 1991-11-20 1999-02-09 Monfort, Inc. Method for preserving food products and food products made thereby
US5374433A (en) * 1991-11-20 1994-12-20 Monfort, Inc. Method for preserving food products
EP0560014A1 (en) * 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
DE4326617C1 (en) * 1993-08-07 1994-06-30 Scherer Siegfried Univ Prof Dr Use of enzymatically active proteins, specific for cell wall lysis of Listeria
US5811093A (en) 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
DE69530553T2 (en) * 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki MEDICAL POLYMER GEL
WO1996004364A1 (en) * 1994-07-29 1996-02-15 The United States Of America, Represented By The Secretary, Department Of Agriculture Saccharomyces treatment to diminish campylobacter and salmonella populations in poultry
US5554380A (en) * 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5612182A (en) 1995-03-10 1997-03-18 Becton, Dickinson And Company Mycobacteriophage specific for the mycobacterium tuberculosis complex
AU7440796A (en) * 1995-10-13 1997-04-30 United States Of America, As Represented By The Secretary Of Agriculture, The In ovo yeast treatment to diminish salmonellae populations in poultry
US5641464A (en) 1995-12-01 1997-06-24 B & B Medical Technologies, Inc. Stethoscope cleansing device and method
US6015816A (en) 1996-02-29 2000-01-18 The Research Foundation Of State University Of New York Antimicrobial compositions
US6322783B1 (en) 1996-08-26 2001-11-27 Seishi Takahashi Bacteriophages, method for screening same and bactericidal compositions using same, and detection kits using same
US6258847B1 (en) * 1996-09-25 2001-07-10 Samir Chachoua Use of 2-mercaptoethanolamine (2-MEA) and related aminothiol compounds and copper(II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
AU5932198A (en) * 1997-01-28 1998-08-18 United States Surgical Corporation Polyesteramide, its preparation and surgical devices fabricated therefrom
WO1998032777A1 (en) * 1997-01-28 1998-07-30 United States Surgical Corporation Polyesteramides with amino acid-derived groups alternating with alpha-hydroxyacid-derived groups and surgical articles made therefrom
AU7113398A (en) * 1997-04-24 1998-11-13 Idaho Research Foundation Inc., The Phages, methods for growing and detecting them and their use
JP3028214B2 (en) * 1997-06-03 2000-04-04 カルピス株式会社 How to administer live birds
TW552304B (en) * 1997-08-08 2003-09-11 Food Industry Res & Dev Inst Rapid identification of microorganisms
US6056954A (en) * 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
DE19828696B4 (en) 1998-06-26 2007-08-02 Volkswagen Ag Vehicle seat with a headrest
AU740562B2 (en) 1998-07-03 2001-11-08 Chr. Hansen A/S Method of preventing bacteriophage infection of bacterial cultures
US20020001590A1 (en) 2000-04-20 2002-01-03 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
US6485902B2 (en) 2000-06-06 2002-11-26 Thomas E. Waddell Use of bacteriophages for control of escherichia coli O157
US6461608B1 (en) 2000-11-22 2002-10-08 Nymox Pharmaceutical Corporation Bacteriophage composition useful in treating food products to prevent bacterial contamination

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414304A2 (en) * 1989-08-21 1991-02-27 Unilever N.V. Aqueous antibacterial compositions comprising surfactant and bacteriophage
WO1995027043A1 (en) * 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
WO1997039111A1 (en) * 1996-04-15 1997-10-23 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
DE19828596A1 (en) * 1997-06-26 1999-02-11 A Daniela Dr Nodar Use of polyvalent bacteriophages
WO2000069269A1 (en) * 1999-05-13 2000-11-23 Exponential Biotherapies, Inc. Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. ALAVIDZE ET AL.: "Isolation of specific lytic phages against multidrug resistant Pseudomonas aeruginosa.", ABSTRACTS OF THE 99TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 99, 30 May 1999 (1999-05-30) - 3 June 1999 (1999-06-03), Washington, DC, US, pages 447, XP002176119 *
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, vol. 33, no. 2, 1985, pages 261 - 274, ISSN: 0004-069X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1985, SLOPEK S ET AL: "RESULTS OF BACTERIOPHAGE TREATMENT OF SUPPURATIVE BACTERIAL INFECTIONS VI. ANALYSIS OF TREATMENT OF SUPPURATIVE STAPHYLOCOCCAL INFECTIONS", XP002176120, Database accession no. PREV198681040614 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835384B (en) * 2007-10-04 2014-07-16 诺沃莱蒂克斯有限公司 Anti-bacteria compositions

Also Published As

Publication number Publication date
US20040247569A1 (en) 2004-12-09
AU2001230889A1 (en) 2001-07-24
EP1250050A2 (en) 2002-10-23
WO2001050872A3 (en) 2001-12-20
WO2001051066A2 (en) 2001-07-19
AU4313101A (en) 2001-07-24
CN1395491A (en) 2003-02-05
EP1250161B1 (en) 2005-12-21
US20120148505A1 (en) 2012-06-14
KR20030009338A (en) 2003-01-29
US20040029250A1 (en) 2004-02-12
US20050175991A1 (en) 2005-08-11
CA2396344A1 (en) 2001-07-19
US20130164374A1 (en) 2013-06-27
ATE313341T1 (en) 2006-01-15
EP1421855A2 (en) 2004-05-26
CA2430501A1 (en) 2001-07-19
WO2001050866A3 (en) 2002-02-07
US6699701B1 (en) 2004-03-02
WO2001051027A2 (en) 2001-07-19
WO2001050872A2 (en) 2001-07-19
US20090053144A1 (en) 2009-02-26
AU2001229342A1 (en) 2001-07-24
ATE280499T1 (en) 2004-11-15
EP1421855A3 (en) 2004-07-14
CA2430498A1 (en) 2001-07-19
EP1250053A2 (en) 2002-10-23
US8003323B2 (en) 2011-08-23
EP1250143A2 (en) 2002-10-23
DE60106727T2 (en) 2005-12-22
WO2001051027A3 (en) 2002-01-10
JP2003519650A (en) 2003-06-24
AU2001249050A1 (en) 2001-07-24
CA2430500A1 (en) 2001-07-19
EP1250050B1 (en) 2004-10-27
US7459272B2 (en) 2008-12-02
WO2001050866A2 (en) 2001-07-19
DE60116052D1 (en) 2006-01-26
CN1230206C (en) 2005-12-07
DE60116052T2 (en) 2006-08-31
DE60106727D1 (en) 2004-12-02
CA2396344C (en) 2009-09-08
EP1250161A2 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
WO2001051066A3 (en) Reduction in bacterial colonization by administering bacteriophage compositions
Montecalvo Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients
HUP0203523A2 (en) The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses
AU2002328972A1 (en) Piperidine derivatives as antibacterial agents
WO2005072826A3 (en) Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
PL372929A1 (en) Composition having bacteristatic and bactericidal activity against bacterial spores and vegetative cells and process for treating foods therewith
AU8030791A (en) Compositions having improved antibacterial properties and use of such compositions in suppressing growth of micro-organisms, e.g. listeria bacteria
DE69713151D1 (en) CYCLOSPORINE DERIVATIVE, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION
HK1091754A1 (en) Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
DE69417920D1 (en) USE BEFORE SIMPLE OR CONJUGATED DEXTRAN FOR THE PRODUCTION OF A MEDICINE FOR PREVENTING OR REDUCING THE RISK OF A BACTERIAL PATHOGENIC INFECTION
CR20210682A (en) Macrocyclic broad spectrum antibiotics
EP3939599A3 (en) Silicate containing compositions and methods of treatment
WO2001082945A3 (en) The use of bacterial phage associated lysing enzymes for treating various illnesses
WO2002002095A3 (en) Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin
EP1060745A3 (en) A composition and method for treating bacterial infection
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
WO2004098500A3 (en) CARBACEPHEM ss-LACTAM ANTIBIOTICS
WO2004060272A3 (en) Delivery of peroxide-generating enzymes to the vaginal tract
CA2332686A1 (en) Novel 13 and 14-membered antibacterial and prokinetic macrolides and their intermediates
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
MXPA02006887A (en) The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections.
EP1585478A4 (en) Use of synergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections
IL172675A0 (en) Benzofuran derivatives and their use in the treatment of microbial infections
MXPA04005179A (en) A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A beta -LACTAM ANTIBIOTIC.
WO2001052869A3 (en) Medicament and method for treating sclerotinia infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001922226

Country of ref document: EP

Ref document number: 2001249050

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001922226

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2430498

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2001922226

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP